High-dose immunoglobulin-dependent chronic inflammatory demyelinating polyneuropathy successfully managed with subcutaneous immunoglobulin using pharmacokinetic analysis

Van den Bergh, 2021, European academy of neurology/peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force-second revision, J. Peripher. Nerv. Syst., 26, 242, 10.1111/jns.12455 Allen, 2018, Individualized immunoglobulin therapy in chronic immune-mediated peripheral neuropathies, J. Peripher. Nerv. Syst., 23, 78, 10.1111/jns.12262 Debs, 2017, A new treatment regimen with high-dose and fractioned immunoglobulin in a special subgroup of severe and dependent CIDP patients, Int. J. Neurosci., 127, 864, 10.1080/00207454.2016.1269328 Doneddu, 2019, Atypical CIDP: diagnostic criteria, progression and treatment response. Data from the Italian CIDP database, J. Neurol. Neurosurg. Psychiatry, 90, 125, 10.1136/jnnp-2018-318714 Tortorici, 2019, Privigen® has similar pharmacokinetic properties in primary and secondary immune deficiency, Int. Immunopharmacol., 66, 119, 10.1016/j.intimp.2018.11.008 Zhang, 2020, Population pharmacokinetic analysis of weekly and biweekly IgPro20 (Hizentra®) dosing in patients with primary immunodeficiency, Int. Immunopharmacol., 81, 10.1016/j.intimp.2019.106005 Waldmann, 1969, Metabolism of immunoglobulins, Prog. Allergy, 13, 1 Dalakas, 2021, The importance of FcRn in neuro-immunotherapies: from IgG catabolism, FCGRT gene polymorphisms, IVIg dosing and efficiency to specific FcRn inhibitors, Ther. Adv. Neurol. Disord., 14, 10.1177/1756286421997381 Wasserman, 2011, Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency, Clin. Pharmacokinet., 50, 405, 10.2165/11587030-000000000-00000